Analysis of Response and Progression Patterns of Tyrosine Kinase Inhibitors in Recurrent or Metastatic Adenoid Cystic Carcinoma: A Post Hoc Analysis of Two KCSG Phase II Trials.
Cancer Res Treat
; 56(4): 1068-1076, 2024 Oct.
Article
en En
| MEDLINE
| ID: mdl-38637966
ABSTRACT
PURPOSE:
In this study, we evaluated 66 patients diagnosed with adenoid cystic carcinoma (ACC) enrolled in two Korean Cancer Study Group trials to investigate the response and progression patterns in recurrent and/or metastatic ACC treated with vascular endothelial growth factor receptor tyrosine kinase inhibitors (VEGFR-TKIs). MATERIALS ANDMETHODS:
We evaluated 66 patients diagnosed with ACC who were enrolled in the Korean Cancer Study Group trials. The tumor measurements, clinical data, treatment outcomes, and progression patterns of therapy were analyzed.RESULTS:
In the 66 patients (53 receiving axitinib and 13 receiving nintedanib), the disease control rate was 61%, and three patients achieved partial response. The median follow-up, median progression-free survival (PFS), overall survival, and 6-month PFS rate were 27.6%, 12.4%, and 18.1% months and 62.1%, respectively. Among 42 patients who experienced progression, 27 (64.3%) showed target lesion progression. Bone metastasis was an independent poor prognostic factor.CONCLUSION:
Overall, most patients demonstrated stable disease with prolonged PFS; however, prominent target lesion progression occurred in some patients. Thus, PFS may capture VEGFR-TKI efficacy better than the objective response rate.Palabras clave
Texto completo:
1
Base de datos:
MEDLINE
Asunto principal:
Carcinoma Adenoide Quístico
/
Progresión de la Enfermedad
/
Inhibidores de Proteínas Quinasas
/
Recurrencia Local de Neoplasia
Idioma:
En
Revista:
Cancer Res Treat
Año:
2024
Tipo del documento:
Article